Difference between revisions of "Aminoglutethimide (Cytadren)"
m |
|||
| Line 14: | Line 14: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
''This medication does not have a specific cancer indication; it is indicated for Cushing Syndrome.'' | ''This medication does not have a specific cancer indication; it is indicated for Cushing Syndrome.'' | ||
| − | *10 | + | *1980-10-29: Initial approval |
==Also known as== | ==Also known as== | ||
Revision as of 15:41, 5 May 2023
General information
Class/mechanism: Inhibitor of adrenalcortical steroid synthesis, blocks conversion of cholesterol to pregnenolone and subsequent synthesis of adrenal steroids, has aromatase inhibitor activity.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it was used
Patient drug information
History of changes in FDA indication
This medication does not have a specific cancer indication; it is indicated for Cushing Syndrome.
- 1980-10-29: Initial approval
Also known as
- Brand names: Aminoblastin, Cytadren, Elipten, Orimentin, Orimeten, Orimetene, Rodazol